Nubeqa plus ADT improved rPFS in mHSPC across all disease volumes, cutting the risk of radiological progression or death by 46%. For patients with metastatic hormone-sensitive prostate cancer (mHSPC), efficacy outcomes were improved following treatment with Nubeqa (darolutamide) in combination […]
Nubeqa Plus ADT Effective in mHSPC Regardless of Disease Volume Read More »
1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose in RCC: © Axel Kock – stock.adobe.com Among patients with renal cell carcinoma (RCC), the Food and Drug Administration (FDA)-approved starting dose of
FDA-Approved Fotivda Dose More Effective Than Reduced Dose in RCC Read More »
A phase 3b/4 trial evaluated health-related quality of life in patients with HER2-positive breast cancer, regardless of the presence of brain metastases. In patients with HER2-positive metastatic breast cancer, health-related quality of life (HRQOL) and neurological function data were relative
Enhertu May Help Preserve Quality of Life in HER2-Positive Breast Cancer Read More »
Tecartus demonstrated similar effectiveness across age groups of patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to a real-world study presented at the 2024 ASH Annual Meeting. Tecartus (brexucabtagene autoleucel) produced similar treatment outcomes in patients aged 60
Tecartus Shows Similar Efficacy Across Age Groups in Leukemia Read More »
The THIO-Libtayo treatment combination may be a beneficial treatment option for patients with NSCLC that is resistant to checkpoint inhibitors. Patients with advanced non-small cell lung cancer (NSCLC) that is resistant to checkpoint inhibitors saw benefits from treatment with THIO
THIO Plus Libtayo May Be Effective in NSCLC Read More »
Patients with resectable (surgically unremovable) non-small cell lung cancer (NSCLC) undergoing treatment with perioperative Opdivo (nivolumab) demonstrated extended event-free survival (EFS; living without complications or disease worsening) versus placebo, according to findings from a phase 3 trial. Updated data from
Perioperative Opdivo Extends Event-Free Survival in Lung Cancer Read More »
Anti–PD-L1 monoclonal antibody benmelstobart plus anlotinib for the frontline treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer, demonstrated improved clinical outcomes compared with Sutent (sunitinib), according to findings from the phase 3 ETER100 trial presented during
Anti-PD-L1 Antibody Drug Combo May Improve Outcomes in Advanced Kidney Cancer Read More »
A treatment combination with Yervoy (ipilimumab) plus Opdivo (nivolumab), compared with standard-of-care therapies, significantly improved 12-month survival in patients with non-clear cell renal cell carcinoma (nccRCC; a type of kidney cancer), according to data presented during the 2024 ESMO Congress. The
Survival Rate Increased With Yervoy-Opdivo Combo in Kidney Cancer Read More »
